Study on the association of 3 SNPs of FcRL3 gene with Graves disease in Chongqing Han population

Chinese Journal of Medical Genetics

Volumn 26, Issue 6, 2009, Pages 681-685

  Zheng, Rui Zhi ^a   Zhao, Zhi Gang ^a   Zhang, Su Hua ^b   Li, Rong ^b  

^a HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

FcRL3 gene; Genetic polymorphism; Graves disease; Single nucleotide

Indexed keywords

LIOTHYRONINE; THYROTROPIN;

ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DNA SEQUENCE; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; GENETIC RISK; GRAVES DISEASE; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BASE SEQUENCE; CASE-CONTROL STUDIES; CHINA; EXONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GRAVES DISEASE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RECEPTORS, IMMUNOLOGIC; RISK FACTORS;

EID: 73849119769     PISSN: 10039406     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.1003-9406.2009.06.017     Document Type: Article

References (16)

1. Ermann J, Fathman CG. Autoimmune diseases: genes, bugs and failed regulation. Nat Immunol, 2001, 2: 759-761.
2. Ringold DA, Nicoloff JT, Kesler M, et al. Further evidence for a strong genetic influence on the development of autoimmune thyroid disease, the California twin study. Thyroid,2002,12 : 647-653.
3. Davis RS, Ehrhardt GR, Leu CM,et al. An extended family of Fc receptor relatives. Eur J Immunol,2005,35 : 674-680.
4. Kochi Y, Yamada R, Suzuki A, et al. A functional variant in FCRL3, encoding Fc receptor-like 3, is associated with rheumatoid arthritis and several autoimmunities. Nat Genet,2005,37 : 478-485.
5. Xu MJ, Zhao R, Cao H, et al. SPAP2, an Ig family receptor containing both ITIMs and ITAMs. Biochem Biophys Res Commun,2002,293 : 1037-1046.
6. Davis RS, Wang YH, Kubagawa H, et al. Identification of a family of Fc receptor homologs with preferential B cell expression. Proc Natl Acad Sci U S A,2001,98 : 9772-9777.
7. Martínez A, Sánchez E, Valdivia A, et al. Epistatic interaction between FCRL3 and NFB1 genes in Spanish patients with rheumatoid arthritis. Ann Rheum Dis,2006,65 : 1188-1191.
8. Eike MC, Nordang GB, Karlsen TH,et al. The FCRL3 -169T>C polymorphism is associated with rheumatoid arthritis and shows suggestive evidence of involvement with juvenile idiopathic arthritis in a Scandinavian panel of autoimmune diseases. Ann Rheum Dis, 2008,67 : 1287-1291.
9. Simmonds MJ, Heward JM, Carr-Smith J, et al. Contribution of single nucleotide polymorphisms within FCRL3 and MAP3K71P2 to the pathogenesis of Graves' disease. J Clin Endocrinol Metab, 2006,91 : 1056-1061.
10. Wellcome Trust Case Control Consortium, Australo-Anglo-American Spondylitis Consortium (TASC), Burton PR, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet, 2007,39 : 1329-1337.
11. Martínez A, Mas A, de Las Heras V, et al. FcRL3 and multiple sclerosis pathogenesis, role in autoimmunity. J Neuroimmunol, 2007,189 : 132-136.
12. Li K, Zhao M, Hou S, et al. Association between polymorphisms of FCRL3, a non-HLA gene, and Behcet's disease in a Chinese population with ophthalmic manifestations. Mol Vis,2008,14 : 2136-2142.
13. Martínez A, Nún̈ez C, Martin MC, et al. Epistatic interaction between FCRL3 and MHC in Spanish patients with IBD. Tissue Antigens,2007,69 : 313-317.
14. Hu X, Chang M, Saiki RK, et al. The functional - 169T/C single-nucleotide polymorphism in FCRL3 is not associated with rheumatoid arthritis in white North Americans. Arthritis Rheum, 2006,54 : 1022-1025.
15. Owen CJ, Kelly H, Eden JA, et al. Analysis of the Fc receptor-like-3 (FCRL3) locus in Caucasians with autoimmune disorders suggests a complex pattern of disease association. J Clin Endocrinol Metab,2007,92 : 1106-1111.
16. Ozdemir V, William-Jones B, Cooper DM, et al. Mapping translational research in personalized therapeutics: from molecular markers to health policy. Pharmacogenomics,2007,8 : 177-185.